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Given the close interaction between tumor cells and stromal cells in the tumor
microenvironment (TME), TME-targeted strategies would be promising for devel-
oping integrated cancer immunotherapy. Cancer-associated fibroblasts (CAFs) are
the dominant stromal component, playing critical roles in generation of the pro-
tumorigenic TME. We focused on the immunosuppressive trait of CAFs, and sys-
tematically explored the alteration of tumor-associated immune responses by
CAF-targeted therapy. C57BL ⁄ 6 mice s.c. bearing syngeneic E.G7 lymphoma, LLC1
Lewis lung cancer, or B16F1 melanoma were treated with an anti-fibrotic agent,
tranilast, to inhibit CAF function. The infiltration of immune suppressor cell types,
including regulatory T cells and myeloid-derived suppressor cells, in the TME was
effectively decreased through reduction of stromal cell-derived factor-1, prosta-
glandin E2, and transforming growth factor-b. In tumor-draining lymph nodes,
these immune suppressor cell types were significantly decreased, leading to acti-
vation of tumor-associated antigen-specific CD8+ T cells. In addition, CAF-targeted
therapy synergistically enhanced multiple types of systemic antitumor immune
responses such as the cytotoxic CD8+ T cell response, natural killer activity, and
antitumor humoral immunity in combination with dendritic cell-based vaccines;
however, the suppressive effect on tumor growth was not observed in tumor-
bearing SCID mice. These data indicate that systemic antitumor immune
responses by various immunologic cell types are required to bring out the effi-
cacy of CAF-targeted therapy, and these effects are enhanced when combined
with effector-stimulatory immunotherapy such as dendritic cell-based vaccines.
Our mouse model provides a novel rationale with TME-targeted strategy for the
development of cell-based cancer immunotherapy.
T umor tissues contain heterogeneous cell types consistingof tumor cells and tumor stromal cells. Most tumor stro-
mal cells, such as immune suppressor cells, vascular endothe-
lial cells, lymphatic endothelial cells, and fibroblasts, help to
maintain pro-tumorigenic homeostasis in the tumor microenvi-
ronment (TME).(1) The interaction between tumor cells and
tumor stromal cells affects the aggressive motility of tumor
cells, which is responsible for the spread of tumors and metas-
tases. Accumulation of immune suppressor cells including reg-
ulatory T cells (Tregs) and myeloid-derived suppressor cells
(MDSCs) in the TME is common in human tumor tissues,(2–4)
leading to suppression of antitumor immune responses with a
subsequently poor prognosis.(5–7)
Cancer immunotherapy has been expected to be a promising
treatment strategy against solid tumors; however, its benefit
remains insufficient to eradicate tumors. The biological com-
plexity of the TME seems to be an obstacle for cancer immu-
notherapy, suggesting that the simple strategy in which only
tumor cells are targeted is hardly adequate to overwhelm the
aggressively growing tumor; therefore, a synergistic TME-
targeted strategy should be required for the development of
more potent cancer immunotherapy.
Among tumor stromal cell types, cancer-associated fibro-
blasts (CAFs) are the dominant component in the TME, and
play critical roles in promoting tumor progression.(8) Cancer-
associated fibroblasts support tumor growth through secretion
of several soluble factors such as epidermal growth factor,
monocyte chemotactic protein-1, hepatocyte growth factor, and
stromal cell-derived factor-1 (SDF-1), which contribute to pro-
liferation, invasion, and metastasis of tumor cells.(9–12) In addi-
tion, CAFs have recently been reported to function as
modulators of immune systems through secretion of transform-
ing growth factor-b (TGF-b) and other immune suppressive
cytokines, creating the milieu in which antitumor immune
responses are impaired.(13) In this context, CAFs have emerged
to be novel targets of cancer immunotherapy; however, it
remains unclear whether antitumor immune responses would
be enhanced by anti-CAF therapy. In this study, we investi-
gated whether a CAF-targeted strategy would improve the
locoregional and systemic antitumor immune responses.
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As a possible agent for this CAF-targeted strategy, we focused
on tranilast, an anti-allergic or antifibrotic agent that has been
used clinically. Tranilast is known to suppress proliferation of
fibroblasts derived from several types of normal tissues,(14–17)
and decrease release of TGF-b from fibroblasts.(18) We previously
reported that tranilast served as a specific inhibitor of CAFs in vi-
tro,(19) showing that tranilast at doses under 100 lM inhibited the
proliferation of CAFs and reduced the levels of SDF-1, TGF-b1,
vascular endothelial growth factor (VEGF), interleukin (IL)-6,
and prostaglandin E2 (PGE2) from CAFs in a dose-dependent
manner. However, tranilast exerted no inhibitory effects on
immune cells or murine tumor cell lines, such as E.G7, LLC1,
and B16, at doses under 100 lM. The induction of Tregs and
MDSCs from their progenitor cells were suppressed in medium in
which CAFs had been cultured in the presence of tranilast.
Here we investigated whether in vivo inhibition of CAF func-
tion would improve locoregional and systemic antitumor immune
responses in a tumor-bearing mouse model. Furthermore, we
report that a CAF-targeted strategy synergistically enhances mul-
tiple types of antitumor immune responses in combination with a
tumor-associated antigen (TAA)-loaded dendritic cell (DC)-based
vaccine in mice bearing several types of tumors.
Materials and Methods
Mice, cells, and reagents. Female C57BL ⁄6J and SCID mice
aged 6 weeks were purchased from Japan SLC (Hamamatsu,
Japan) and CLEA Japan (Tokyo, Japan), respectively. The
mice were maintained under specific pathogen-free conditions.
All mouse experiments were carried out in compliance with
the Guidelines for Animal Experimentation from Shiga Univer-
sity of Medical Science (Shiga, Japan).
The mouse lymphoma cell line E.G7 that expresses ovalbu-
min (OVA) and the natural killer (NK) cell-sensitive cell line
YAC-1 were purchased from ATCC (Manassas, VA, USA),
and were passaged for fewer than 6 months. The mouse Lewis
lung carcinoma cell line LLC1 and the mouse melanoma cell
line B16F1 were provided by the Cell Resource Center for
Biomedical Research, Tohoku University (Sendai, Japan).
Tranilast (N-[3,4-dimethoxycinnamoyl]-anthranilic acid)
(Sigma-Aldrich, St. Louis, MO, USA) was dissolved in DMSO
at a concentration of 25 mM as a stock solution.
Tumor-bearing mouse models and in vivo CAF inhibi-
tion. Female C57BL ⁄6J mice were inoculated s.c. in the right
flank with 5 9 105 tumor cells. Seven days after tumor inocu-
lation, when s.c. tumors had grown to 5–7 mm in diameter,
the mice were randomly grouped. To inhibit the function of
CAFs, some groups of mice were treated with 100 lL of
200 lM tranilast directly into the established tumor every day
for 2 weeks. Mice in control groups were given 0.8% DMSO.
Along with the DC-based vaccines, some groups of mice were
s.c. administered 1 9 106 TAA-loaded DCs suspended in
100 lL PBS near the tumor on days 7, 13, and 19. Five days
after the final administration of tranilast, the tumor tissues,
tumor-draining lymph nodes (TDLNs), spleens, and sera were
harvested from mice. Subcutaneous lymph nodes at the right
flank of normal mice were harvested as a counterpart of
TDLNs in tumor-bearing mice and used in the following
experiments. Volumes of tumors harvested from the mice were
calculated using the following formula: length 9 width2 ⁄2.
Unless specified otherwise, each experimental or control group
comprised five mice.
Western blot analysis. Tumors harvested from the mice were
lysed with lysis buffer (1 mM EDTA, 20 mM Tris-HCl in
distilled water). The protein of tumor lysate (5 lg ⁄ lane for a-
smooth muscle actin [a-SMA] or 75 lg ⁄ lane for SDF-1) was
subjected to 7.5% SDS-PAGE and transferred to a PVDF
membrane. The membrane was incubated with rabbit poly-
clonal anti-mouse a-SMA (1:5000; Abcam, Cambridge, UK)
or rabbit polyclonal anti-mouse SDF-1 (1:3000; Abcam) anti-
bodies, followed by the standard Western blotting procedure,
as described previously.(20)
Quantification of levels of PGE2 and TGF-b1. The levels of
PGE2 and TGF-b1 in tumor tissues were measured using
Parameter Prostaglandin E2 Assay and TGF-b1 Quantikine
ELISA kit (R&D Systems, Minneapolis, MN, USA), respec-
tively.
Preparation of DC-based vaccine. The DC-based vaccine was
prepared as described previously.(21) Bone marrow cells from
the femurs of C57BL ⁄6J mice were cultured for 7 days in the
presence of recombinant mouse granulocyte macrophage col-
ony-stimulating factor and IL-4 (R&D Systems) with final con-
centrations of both of 20 ng ⁄mL. Induced immature DCs were
matured in culture for 24 h in the presence of 0.1 KE ⁄mL
OK432 (Chugai Pharmaceutical Co., Tokyo, Japan). To pre-
pare the DC-based vaccine, mature DCs were pulsed with
1 lM TAA-derived MHC class I peptides, SIINFEKL for
E.G7, EGSRNQDWL for B16F1, and FEQNTAQP and
FEQNTAQA for LLC1,(22) at 37°C for 2 h.
Immunohistochemistry. The tumor tissues were frozen in the
optimal cutting temperature compound, sliced, and fixed with
ethanol. The sections were incubated with rabbit polyclonal
anti-mouse a-SMA antibody (1:200; Abcam) for the detection
of CAFs, or anti-mouse Foxp3 antibody (clone, FJK-16s, 1:50;
eBioscience, San Diego, CA, USA) for the detection of Tregs,
followed by incubation with biotinylated anti-rabbit IgG
(1:200 dilution). For the detection of MDSCs, the sections
were incubated with FITC-conjugated anti-CD11b (clone, M1
⁄70) and phycoerythrin (PE)-conjugated anti-Gr-1 (clone,
Ly-6G) antibodies, and examined using a BX-61 fluorescent
microscope (Olympus, Tokyo, Japan).
Flow cytometry. To detect Tregs, cells were stained with PE-
conjugated anti-CD4 (clone, L3T4), FITC-conjugated anti-
CD25 (clone, 7D4), and allophycocyanin-conjugated anti-
Foxp3 (clone, FJK-16s) antibodies using an anti-mouse ⁄ rat
Foxp3 staining set (eBioscience), according to the manufac-
turer’s instructions. To detect MDSCs, cells were stained with
FITC-conjugated anti-CD11b (clone, M1 ⁄70; eBioscience) and
PE-conjugated anti-Gr-1 (clone, Ly-6G; eBioscience) antibod-
ies.
To evaluate TAA-specific CD8+ T cell responses that had
been elicited in the mice, TDLN cells or spleen cells were
stimulated with or without 1 lM OVA-derived MHC class I
epitope peptide (SIINFEKL) for 16 h. The cells were stained
with PE-conjugated anti-CD8 (clone, Ly-2; eBioscience) and
FITC-conjugated anti-c-interferon (IFN-c) antibodies (clone,
XMG1.2; eBioscience), as previously described.(21)
The stained cells were analyzed using a FACSCalibur flow
cytometer (BD Biosciences, San Jose, CA, USA). The data
were visualized as dot blots using CellQuest software (BD
Biosciences).
Cytotoxicity assay. Spleen cells were stimulated with 1 lM
OVA-derived MHC class I epitope peptide (SIINFEKL) in the
complete medium containing 1 ng ⁄mL recombinant mouse IL-
2 (Wako Pure Chemical Industries, Osaka, Japan) for 5 days.
Then, the cells were cultured with 1 9 104 E.G7 or YAC-1
cells at various effector ⁄ target ratios for 4 h. The amount of
lactate dehydrogenase released from lysed target cells in the
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supernatants was estimated using a CytoTox 96 Non-Radioac-
tive Cytotoxicity Assay (Promega, Madison, WI, USA).
Statistical analysis. Statistical significance of the differences
between groups was analyzed using Student’s t-test. P-values
lower than 0.05, 0.01, and 0.001, considered statistically sig-
nificant, are indicated as *, **, and ***, respectively, in each
figure. Representative results from three independent experi-
ments that produced similar results are shown.
Results
Reduction of immune suppressor cells in TME through inhibi-
tion of CAF function. To inhibit CAF function in vivo, we
administered tranilast into the established E.G7 tumors in
tumor-bearing mice. Immunohistochemistry of tumor tissues
showed that intratumoral administration of vehicle (DMSO)
alone did not reduce the number of a-SMA+ cells compared
with that in the case of PBS treatment alone, whereas the num-
ber of a-SMA+ cells was significantly reduced after repeated
intratumoral administrations of tranilast compared with that
after vehicle treatment (P < 0.001) (Figs 1a,S1). Concerning
soluble factors secreted from CAFs, the level of SDF-1 in
tumor tissues was significantly decreased, associated with
reduction of CAFs (anti-CAFs vs vehicle, P = 0.007) (Figs 1b,
S2). Furthermore, levels of immunosuppressive cytokines such
as PGE2 and TGF-b1 in tumor tissues were also significantly
reduced by inhibition of CAF function (anti-CAFs vs vehicle,
P < 0.05, respectively) (Fig. 1c,d).
In the tumor-bearing mice, we examined the infiltration of
CD4+ cells and CD8+ T cells in the TME. The numbers of
CD4+ cells as well as CD8+ cells were significantly increased
in tumor tissues of mice treated with anti-CAF therapy com-
pared with that in control mice (anti-CAFs vs vehicle,
P < 0.05, respectively) (Fig. S3). Next, we investigated the
association between CAFs and suppressor immune cells in the
TME. The number of Foxp3+ Tregs was significantly reduced
in tumor tissues of mice treated with anti-CAF therapy com-
pared with that in control mice (anti-CAFs vs vehicle,
P = 0.0043) (Fig. 1e). The number of CD11b+Gr-1+ MDSCs
in tumor tissues was also significantly reduced compared with
(a) (b)
(c) (d)
(e) (f)
Fig. 1. Reduction of infiltrative suppressor
immune cells in tumor microenvironment through
inhibition of cancer-associated fibroblast (CAF)
function. Mice bearing E.G7 tumors were treated
with both tranilast and a dendritic cell (DC)-based
vaccine. Five days after the final treatment, tumor
tissues were harvested from the mice. (a) Numbers
of a-smooth muscle actin (a-SMA)+ CAFs in the
tumor tissues were determined by
immunohistochemical staining. (b) Expression of
stromal cell-derived factor-1 (SDF-1) in tumor tissues
was analyzed by Western blotting. The levels of
prostaglandin E2 (PGE2) (c) and transforming
growth factor-b1 (TGF-b1) (d) in tumor tissues were
measured by ELISA. Infiltration of Foxp3+
regulatory T cells (black arrowheads) (e) and Gr-1+
myeloid-derived suppressor cells (white arrowheads)
(f) in tumor tissues was analyzed by
immunohistochemical staining. Bars represent
mean  SD of three independent experiments.
*P < 0.05, **P < 0.01, ***P < 0.001. N.S., not
significant.
© 2014 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd
on behalf of Japanese Cancer Association.
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that in control mice (anti-CAFs vs vehicle, P < 0.001)
(Fig. 1f). When mice were treated with anti-CAF therapy com-
bined with a TAA-loaded DC-based vaccine, the suppressive
effect of anti-CAF therapy on migration of both Foxp3+ Treg
cells (DC + anti-CAFs vs anti-CAFs, P = 0.013) and
CD11b+Gr-1+ MDSCs (DC + anti-CAFs vs anti-CAFs,
P = 0.010) in the TME was enhanced (Fig. 1e,f). These results
indicate that CAFs are critically involved in the migration of
immune suppressor cells.
Improvement of antitumor immune responses in TDLNs
through inhibition of CAF function. Tumor-draining lymph
nodes are critical sites for generation of antitumor immune
responses as various soluble factors and immune suppressor
cells flowing from the TME into TDLNs regulate the immune
system.(23,24) Indeed, TDLNs of tumor-bearing mice with vehi-
cle treatment contained more immune suppressor cells than did
those of normal mice without tumors (Fig. 2a,b). Thus, we
examined whether the reduction of immune suppressor cells in
the TME by inhibition of CAF function would affect the
immune system in TDLNs. Our results revealed that anti-CAF
therapy contributed to reduction of CD4+CD25+Foxp3+ Tregs
(anti-CAFs vs vehicle, P < 0.01) (Figs 2a,S4) and CD11b
+Gr-1+ MDSCs (anti-CAFs vs vehicle, P < 0.001) (Fig. 2b) in
TDLNs.
We then evaluated whether the reduction of suppressor
immune cells contributed to activation of TAA-specific CD8+
T cells in TDLNs of E.G7-bearing mice. The TAA-specific
CD8+ T cells that produced IFN-c in TDLNs were increased
in mice treated with anti-CAF therapy alone (anti-CAFs vs
vehicle, P = 0.023), more significantly in mice that received
the DC-based vaccine in combination with anti-CAF therapy
(DC + anti-CAFs vs anti-CAFs, P < 0.001; DC + anti-CAFs
vs DC + vehicle, P < 0.001) (Fig. 2c). These results indicated
that the reduction of immune suppressor cells elicited enhance-
ment of immune effector cell functions as antitumor immune
responses in TDLNs.
Improvement of systemic cellular and humoral antitumor
immune responses through anti-CAF therapy. Next, we exam-
ined whether systemic immune responses in spleens were
improved by inhibition of CAFs, as seen in TDLNs. The per-
centage of CD4+CD25+Foxp3+ Tregs was reduced in spleens
of mice treated with anti-CAF therapy, but with minimal
effects (Fig. 3a). In contrast, the number of CD11b+Gr-1+
MDSCs was significantly reduced in spleens of mice treated
(a)
(b)
(c)
Fig. 2. Improvement of antitumor immune
responses in tumor-draining lymph nodes (TDLNs)
through inhibition of cancer-associated fibroblast
(CAF) function. Mice bearing E.G7 tumors were
treated with a dendritic cell (DC)-based vaccine in
combination with or without anti-CAF therapy. Five
days after the final treatment with tranilast, the
populations of CD4+CD25+Foxp3+ regulatory T cells
(a) and CD11b+Gr-1+ myeloid-derived suppressor cells
(b) in TDLNs were analyzed by flow cytometry.
(c) TDLNs cells were stimulated with ovalbumin
(tumor-associated antigen)-derived MHC class I
peptide in vitro, then the population of interferon-
c+CD8+ T cells was analyzed by flow cytometry
(closed square, with tumor-associated antigen
stimulation in vitro; open square, control). Bars
represent mean  SD of three independent
experiments. **P < 0.01, ***P < 0.001. N.S., not
significant.
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with anti-CAF therapy compared with those in control mice
(anti-CAFs vs vehicle, P = 0.013) (Fig. 3b). Furthermore, the
reduction of CD11b+Gr-1+ MDSCs in spleens was more signif-
icant in mice simultaneously treated with anti-CAF therapy
and the DC-based vaccine than in mice treated with anti-CAF
therapy alone (P = 0.0073).
We also investigated the effects of anti-CAF therapy on
TAA-specific CD8+ T cell responses in spleens. The number
of TAA-specific CD8+ T cells that produced IFN-c in spleens
was increased in mice treated with anti-CAF therapy compared
with those in control mice (anti-CAFs vs vehicle, P < 0.001)
(Fig. 3c). The DC-based vaccine activated TAA-specific CD8+
T cell responses in spleens (DC + vehicle vs vehicle,
P < 0.001), whereas the combination of the DC-based vaccine
and anti-CAF therapy had a synergistic effect on the activation
of TAA-specific CD8+ T cells (DC + anti-CAFs vs anti-CAFs,
P < 0.001; DC + anti-CAFs vs DC + vehicle, P = 0.0031).
Corresponding to IFN-c production by CD8+ T cells in the
spleens, cytotoxic effects against E.G7 tumor cells were
enhanced more significantly in mice simultaneously treated
with anti-CAF therapy and the DC-based vaccine than in mice
treated with the DC-based vaccine alone (P < 0.001) (Fig. 4a).
We investigated whether other components of the immune
system were improved in mice treated with anti-CAF therapy.
Activity of NK cells was enhanced in mice treated with anti-
CAF therapy compared with that in control mice (anti-CAFs
vs vehicle, P = 0.0053) (Fig. 4b). The DC-based vaccine
enhanced NK activity (DC + vehicle vs vehicle, P < 0.001)
and induced a synergistic effect on activation of NK cells in
combination with anti-CAF therapy (DC + anti-CAFs vs
DC + vehicle, P < 0.001) (Fig. 4b). In terms of humoral
immune responses against TAA, anti-OVA antibody levels
were determined by ELISA(25), revealing that they were
increased in sera of mice treated with anti-CAF therapy com-
pared with those in control mice (anti-CAFs vs vehicle,
P < 0.001) (Fig. 4c). Furthermore, humoral immune responses
to the target antigen were effectively enhanced in mice treated
with the DC-based vaccine in combination with anti-CAF ther-
apy (DC + anti-CAFs vs DC + vehicle, P = 0.048). These
results indicated that systemic cellular and humoral antitumor
(a)
(b)
(c)
Fig. 3. Improvement of systemic antitumor
immune responses associated with inhibition of
cancer-associated fibroblast (CAF) function. Mice
bearing E.G7 tumors were treated with a dendritic
cell (DC)-based vaccine in combination with or
without anti-CAF therapy. Five days after the final
treatment with tranilast, the populations of
CD4+CD25+Foxp3+ regulatory T cells (a) and
CD11b+Gr-1+ myeloid-derived suppressor cells (b) in
spleen cells were analyzed by flow cytometry. (c)
Spleen cells were stimulated with ovalbumin (tumor-
associated antigen)-derived MHC class I peptide in
vitro, then the population of interferon-c+CD8+ T
cells was analyzed by flow cytometry (closed square,
with tumor-associated antigen stimulation in vitro;
open square, control). Bars represent mean  SD of
three independent experiments. *P < 0.05,
**P < 0.01, ***P < 0.001. N.S., not significant.
© 2014 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd
on behalf of Japanese Cancer Association.
Cancer Sci | February 2015 | vol. 106 | no. 2 | 138
Original Article
CAF-targeted strategy in DC vaccine www.wileyonlinelibrary.com/journal/cas
immune responses were enhanced by inhibition of CAF func-
tion in vivo.
Enhancement of DC-based vaccine potency in combination
with anti-CAF therapy. We examined whether improved sys-
temic antitumor immune responses contributed to suppression
of tumor growth in various tumor-bearing mouse models. In
E.G7 tumor-bearing mice, tumor growth was suppressed by
anti-CAF therapy (anti-CAFs vs vehicle, P = 0.012); in addi-
tion, the combination of the DC-based vaccine and anti-CAFs
therapy suppressed tumor growth more effectively than did the
DC-based vaccine alone (DC + anti-CAFs vs DC + vehicle,
P < 0.001) (Fig. 5a). As well as in mice bearing B16F1 or
LLC1, the DC-based vaccine in combination with anti-CAF
therapy had a synergistic suppressive effect on tumor growth
(DC + anti-CAFs vs DC + vehicle, P < 0.001 or P = 0.041,
respectively) (Fig. 5b,c).
Finally, to confirm that suppression of tumor growth was
due to improved immune responses by anti-CAF therapy, we
investigated whether inhibition of CAFs directly contributed to
suppression of tumor growth in SCID mice. Proliferation of
CAFs was effectively suppressed by anti-CAF therapy in SCID
mice bearing E.G7 tumors (anti-CAFs vs vehicle, P < 0.001)
(Fig. 5d). Although infiltration of Gr-1+ cells in tumor tissues
was decreased (anti-CAFs vs vehicle, P = 0.012) while that of
NK cells was increased (anti-CAFs vs vehicle, P = 0.040)
(Fig. S5), a suppressive effect on tumor growth was not
observed (anti-CAFs vs vehicle, P = 0.86) (Fig. 5e). These
results suggest that CAFs have little direct supportive effect on
tumor growth, but play a critical role in immune modulation in
TME and that inhibition of CAF function in vivo enhances the
potency of DC-based vaccines by dampening the immune sup-
pressive system.
Discussion
In this study, we focused on the supportive role of CAFs in
suppression of antitumor immune responses. Inhibition of CAF
function reduced the infiltration of immune suppressor cells
into the TME and TDLNs, thereby improving both cellular
and humoral antitumor immune responses in combination with
TAA-loaded DC-based vaccines.
As a possible agent for a CAF-targeted strategy, we focused
on tranilast, an anti-allergic or antifibrotic agent that has been
used clinically. Our previous data indicated that tranilast at
doses under 100 lM served as a specific inhibitor against
CAFs in vitro, but exerted no inhibitory effects on immune
cells such as CD4+, CD8+, and NK cells(19) as well as DC
(Fig. S6). In addition, tranilast at doses under 100 lM did not
affect the cell viability of murine tumor cells, such as E.G7,
LLC1, and B16F1.(19) Given that the tranilast concentration in
tumor tissues in our mouse models was lower than 50 lM
after repeated tranilast treatment (data not shown), it is consid-
ered that administration of tranilast into the tumor exerts no
direct inhibitory effect on tumor cells. Although tranilast has
been reported to exert an inhibitory effect on tumor cells and
immune cells, the concentrations of tranilast that had been
applied in previous studies were 100–300 lM.(26) Given that
the Cmax of tranilast at the therapeutic dose in humans
(300 mg ⁄day) is estimated to be 100 lM in peripheral
blood,(27) the concentrations of tranilast that had been applied
in previous studies were quite excessive, indicating that much
higher doses of tranilast would be required to exert the inhibi-
tory effect on tumor cells and immune cells.
The interaction between CAFs and immune suppressor cells
in the TME needs to be further elucidated for the development
of cancer immunotherapy. Our data showed that infiltration of
MDSCs into the TME was reduced by anti-CAF therapy,
accompanying significant reduction in levels of SDF-1 and
PGE2 in the tumor tissue. As recruitment of MDSCs to the
TME are induced by several factors, including stem cell factor,
SDF-1, PGE2, VEGF, and MMP,
(28–31) the decreased levels of
SDF-1 and PGE2 in the TME, caused by inhibition of CAFs’
function, could have contributed to the reduced migration of
MDSCs into the TME.
The association between CAFs and the induction of Treg
cells was reported, demonstrating that TGF-b and VEGF were
(a)
(b)
(c)
Fig. 4. Enhancement of multiple components of
antitumor immune systems by inhibition of cancer-
associated fibroblast (CAF) functions in vivo. Mice
bearing E.G7 tumors were treated with a dendritic
cell (DC)-based vaccine in combination with or
without anti-CAF therapy. Five days after the final
treatment with tranilast, spleens and sera were
harvested from the mice. (a) Spleen cells were
stimulated with ovalbumin (tumor-associated
antigen)-derived MHC class I peptide and
interleukin-2 for 5 days in vitro, then were
cocultured with E.G7 cells for 4 h. The cytotoxicity
against E.G7 cells was measured by lactate
dehydrogenase release assay. (b) Natural killer
activity in spleen cells was evaluated by the lactate
dehydrogenase release assay that targeted YAC-1
cells. (c) Levels of anti-ovalbumin antibody
production in sera were measured by ELISA. Bars
represent mean  SD of three independent
experiments. *P < 0.05, **P < 0.01, ***P < 0.001.
N.S., not significant.
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upregulated in CAFs in the region containing a high number
of Treg cells, and these CAFs were more efficient in inducing
Treg cells from na€ıve CD4+ T cells.(32) Our previous data
showed that TGF-b release from E.G7 cells was not affected
by tranilast at doses under 100 lM;(19) thus, in mice treated
with anti-CAF therapy, the decreased level of TGF-b in the
TME was induced through anti-CAF therapy. In mice treated
with the DC-based vaccine alone, the level of TGF-b was sig-
nificantly decreased in the TME, which would be caused by
the effective suppression of tumor growth through the induc-
tion of CTLs. Therefore, in mice treated with the DC-based
vaccine in combination with anti-CAF therapy, the level of
TGF-b in the TME was significantly decreased, contributing to
the effective reduction of Treg cells there. The decreased level
of SDF-1 in the TME by inhibition of CAFs would be associ-
ated with the reduced migration of Treg cells in the TME, as
blocking of the CXCR4–CXCL12 axis was reported to prevent
migration of Treg cells into the TME.(33) Taken together,
CAFs play critical roles in migration to, and induction of,
immune suppressor cells in the TME, thus the immune sup-
pressive TME would be improved by inhibition of CAF
function. In addition, the potency of the DC-based vaccine was
synergistically augmented when combined with anti-CAF ther-
apy, contributing to effective suppression of tumor growth and
decreased levels of immunosuppressive cytokines in tumor tis-
sues. Therefore, this combination therapy would more effec-
tively improve the immune suppressive TME.
Tumor-draining lymph nodes are primary sites for induction
and suppression of antitumor immune responses as tumor tis-
sue-derived soluble factors and tumor-associated immune cells
flow into TDLNs, modifying the functional characteristics of
downstream TDLNs.(23,24) Activation of immune suppressor
cells in TDLNs induces systemic tolerance against TAA,(28) so
dampening of immune suppressive responses in TDLNs could
improve systemic antitumor immune responses. Our data
showed that the improved immune responses in TDLNs by
anti-CAF therapy was associated with enhanced systemic
TAA-specific CD8+ T cell responses, and a combination of the
DC-based vaccine and anti-CAF therapy enhanced the potency
of the DC-based vaccine. In addition to the CD8+ T cell
response, the TAA-specific humoral response and NK activity
were significantly improved in mice treated with anti-CAF
(a)
(b) (c)
(d)
(e)
Fig. 5. Enhancement of dendritic cell (DC)-based
vaccine potency in combination with anti-
cancerassociated fibroblast (CAF) therapy. Mice
were inoculated s.c. with (5 9 105) tumor cells.
Seven days after tumor inoculation, the mice were
treated with a DC-based vaccine s.c. near the
tumors on days 7, 13, and 19, in combination with
or without intratumoral treatment with tranilast
every day for 2 weeks. Twenty-four days after
tumor inoculation, volumes of E.G7 (a, left), B16F1
(b), and LLC1 tumors (c) were measured. Tumor
volumes in E.G7 tumor-bearing mice were
monitored every 3–4 days (a, right). SCID mice
bearing E.G7 tumors were administered tranilast
into tumors every day for 2 weeks. Five days after
the final treatment with tranilast, tumor tissues
were harvested from the mice. (d) a-Smooth muscle
actin+ CAFs in the tumor tissues were evaluated by
immunohistochemical staining. (e) Twenty-four days
after tumor inoculation, volumes of tumors were
measured. Each group had 5–10 mice. Bars indicate
the median tumor volume  SD of the group.
*P < 0.05, **P < 0.01, ***P < 0.001. N.S., not
significant.
© 2014 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd
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therapy. It was previously reported that PGE2 released by
CAFs dampened activity of NK cells by downregulation of
NKp44 and NKp30,(34) and thus NK activity might be recov-
ered by direct inhibition of CAF function. Based on the results
of our previous study showing that inhibition of TGF-b func-
tion in TDLNs enhanced systemic immune responses,(35)
immune modulation of TDLNs through inhibition of CAF
function might enhance antitumor cellular and humoral
immune responses.
Several strategies for targeting CAFs in cancer therapy
have been reported. Of the molecules that are expressed in
CAFs, fibroblast activation protein (FAP) has emerged as the
promising therapeutic target.(36) In tumor-bearing animal
models, FAP mRNA-transduced DC-based vaccines and DNA
vaccines encoding FAP exerted suppressive effects on tumor
growth.(37–40) In terms of immune responses, the previous
papers reported that the infiltration of immune suppressor
cells was reduced through inhibition of FAP+ cells, consistent
with our present data. In addition, some published works
reported that antitumor CTL responses were enhanced in
combination with the cytotoxic chemotherapy.(38,39) These
studies showed that inhibition of CAFs contributed to
enhancement of effector cell responses, highlighting the
immune suppressive trait of CAFs. The tumor-bearing SCID
mouse model in our study showed that anti-CAF therapy
suppressed the proliferation of CAFs but exerted no suppres-
sive effect on tumor growth. These data suggest that simulta-
neous stimulation of antitumor immune effector responses
would be combined to elicit potent antitumor effects in a
CAF-targeted strategy.
This study showed the critical roles of CAFs in generating
the immunosuppressive and pro-tumorigenic TME through
supporting the infiltration of immune suppressor cells. Immune
modulation through inhibition of CAF function improved
regional and systemic antitumor immune responses, thereby
enhancing the potency of the DC-based vaccine immunother-
apy. Our mouse models provide a novel rationale with a TME-
targeted strategy for the development of cell-based cancer
immunotherapy.
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Fig. S1. Anti-cancer-associated fibroblast effects of tranilast on tumor tissues.
Fig. S2. Reduced level of stromal cell-derived factor-1 (SDF-1) in tumor microenvironment through inhibition of cancer-associated fibroblast func-
tion.
Fig. S3. Increased infiltration of CD4+ and CD8+ cells in tumor microenvironment through inhibition of cancer-associated fibroblast function.
Fig. S4. Reduction of regulatory T cells in tumor-draining lymph nodes through inhibition of cancer-associated fibroblast function.
Fig. S5. Preferable effects of anti-cancer-associated fibroblast therapy in a SCID mouse model.
Fig. S6. Non-inhibitory effects of tranilast on maturation of dendritic cells.
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